Oasmia Pharma Revenue, Profits - OASM Annual Income Statement

Add to My Stocks
$3.45 $0.89 (34.77%) OASM stock closing price Sep 21, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Oasmia Pharma stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2018 impacts the OASM stock. Investors typically check year over year or quarter over quarter revenue growth. The Oasmia Pharma profit and loss statement for 2018 shows a net profit of $-14.23M. Profits for last year was $-18.33M. Apart from this an investor should also check Oasmia Pharma assets and Oasmia Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is May - Apr20182017201620152014
Oasmia Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)---1.35M1.04M
Oasmia Pharma Gross Profit
Research & Development Expense-----
Selling General & Admin Expense6.12M8.45M8.75M5.99M6.32M
Income Before Depreciation Depletion Amortization-6.09M-8.77M-8.55M-7.06M-7.36M
Depreciation Depletion Amortization-----
Non Operating Income5.84M6.79M7.11M6.82M6.94M
Interest Expense1.73M2.27M1.17M1.27M1.1M
Oasmia Pharma Pretax Income
Provision for Income Taxes-----
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-14.23M-18.33M-17.23M-15.81M-16.11M
Extraordinary Items & Discontinued Operations-----
Oasmia Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS55.4M37.67M33.92M--
Average Shares used to compute Basic EPS55.4M37.67M33.92M--
Income Before Nonrecurring Items-14.23M-18.35M-16.82M--
Income from Nonrecurring Items-----
Oasmia Pharma Earnings Per Share Basic Net
Oasmia Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.26-0.49-0.50--
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.

The key things to look for in an income statement while doing Oasmia Pharma stock analysis are:

  • Topline: A growing topline, as seen from the Oasmia Pharma revenue chart, as isn't the case with Oasmia Pharma indicates a sagging business. One needs to compare the YoY topline or sales growth of OASM stock with its peers like MTEM stock and CTIC stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: Most businesses like Oasmia Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The OASM financials along with Oasmia Pharma historical stock prices provide a lot of details about the firm.

Oasmia Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield

Annual Income Statements - Oasmia Pharmaceutical AB - American Depositary Shares Industry Peers

CTI BioPharma income statement, MOLECULAR TEMPL income statement, PROCESSA PHARMA income statement, Vernalis income statement